chevron_leftBack
As of 13 June 2026, Ascletis Pharma Inc. has a market cap of $2.24B USD, ranking #6546 globally and #1533 in China.
It ranks #518 in the Healthcare sector, and #99 in the Biotechnology industry.
Key Stats
Market Cap
$2.24BUSD
17.52B HKD
Enterprise Value
$1.97BUSD
15.41B HKD
Revenue (TTM)
$287.96KUSD
2.26M HKD
EBITDA (TTM)
-$66.97MUSD
-524.85M HKD
Net Income (TTM)
-$51.1MUSD
-400.48M HKD
Forward PE
32.9
PS Ratio
7762.9
PB Ratio
8.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jinzi Jason Wu
open_in_new
Employees
208
Founded
2013
Website
ascletis.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.2% | -9.5% | -2.3% | 21% | 80% | 147% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
1672
歌礼制药有限公司 Ordinary Shares
ISIN: KYG0520K1094
Shares Out.:
Shares Outstanding:
1.059B1
Shares Float:
300.665M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
16.47 HKD | |
|
2VJ
歌礼制药有限公司 Ordinary Shares
ISIN: KYG0520K1094
|
1.79 EUR | |
|
ASCLF
歌礼制药有限公司 Ordinary Shares
ISIN: KYG0520K1094
Shares Out.:
Shares Outstanding:
891.427M1
Shares Float:
173.605M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.90 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ascletis Pharma Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SHEK: 2269
|
$17.44B
680%
136.71B HKD
|
25.3
|
|
SHEK: 1093
|
$12.2B
446%
95.58B HKD
|
22.1
|
|
SHE: 002422
|
$8.0B
258%
54.23B CNY
|
34.4
|
|
|
$7.33B
228%
49.69B CNY
|
-
|
||
SHEK: 1530
|
$7.08B
217%
55.5B HKD
|
5.8
|
|
SHE: 300347
|
$6.72B
201%
45.52B CNY
|
61.6
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
8K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
7K%
|
19.0
|
|
EBR: ARGX
|
$47.84B
2K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
2K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
2K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
2K%
33.71B CHF
|
37.2
|
chevron_leftBack